VIDEO: CD19–directed CAR T cells shows promise in advanced lymphomas

Treatment with JCAR017 showed promise in patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma, according to the phase 1 TRANSCEND NHL trial presented at the ASCO Annual Meeting, June 2017.

Jeremy Slade Abramson, MD, clinical director of the Center for Lymphoma at Massachusetts General Hospital Cancer Center, and colleagues evaluated the safety and efficacy of JCAR017 (Juno Therapeutics) in 28 patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, grade 3B follicular lymphoma or mantle cell lymphoma.

Patients demonstrated high complete response rates. Further, toxicities appeared manageable and occurred at rates lower than those reported for other CD19–directed CAR T-cell products.

“Though our follow-up is still relatively brief, many of these remissions are proving durable and will hopefully prove curative,” Abramson said.

Next, Abramson and colleagues plan to expand the study into a pivotal population in hopes of FDA approval.

“We’re very optimistic that moving forward, we’ll see very exciting results in an ongoing way that hopefully lead this drug to being available for patients worldwide,” he added.

Video at: https://www.healio.com/hematology-oncology/lymphoma/news/online/%7B011c8992-9847-4131-8fb5-ed961149343a%7D/video-cd19directed-car-t-cells-shows-promise-in-advanced-lymphomas

wmay13241

Upcoming CAR-T coverage at Bloomberg News?

For anyone who would like to share their stories of how they were able to gain access to CAR-T therapy, or whether they are still waiting to gain access…

I received the email below a few days ago from one of the lymphoma Yahoo Groups I am a member of. I’ve since shared my CAR-T story with Michelle, but my story may be less relevant than some of yours, since I did CAR-T way back in 2015. 🙂

Please read Michelle’s email below and see if you may be interested:

Hi. I’m a journalist at Bloomberg News, and I’m writing a story about Car-T therapy for DLBCL. I am hoping to find a patient who is willing to share their story and perspective about trying to get into one of the studies or is waiting for the therapy to be approved. We and others have written about the actual treatment and how that process occurs. I want to explore the issues that come with waiting for access, as that is likely to be a bigger issue once the approach is approved. I appreciate the help!

The story will have a US focus since the approval is supposed to come this year from the FDA. I am based in Minneapolis but can call anywhere to anyone, anytime. Thanks so much for any help!

Michelle Cortez
Email: mcortez@bloomberg.net
Phone: 612-991-8887

ICML 2017 – Prof. Stephen J. Schuster from the Abramson Cancer Center, Philadelphia, PA, US, discusses interim results from the phase II JULIET trial of CTL019 in adult patients with R/R DLBCL | LymphomaHub

Dr. Schuster details the entire process using Novartis’s CTL019 CAR-T at U. Penn.

http://www.lymphomahub.com/medical-information/prof-stephen-j-schuster-interim-results-of-the-juliet-trial-of-ctl019-in-rr-dlbcl-icml-2017

As a side note, my wife and I met with Dr. Schuster and his team for over 2 hours in February 2015. I found him to be a warm, down-to-earth doctor. I almost enrolled in his trial, before my wife happened to discover online that Memorial Sloan-Kettering in NYC, where I was already a patient, had just started enrolling Follicular Lymphoma patients in their CAR-T trial. (I’ve been told I’m fNHL patient #1 to complete CAR-T at MSK.)